Xenon Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.95 Insider Own0.20% Shs Outstand65.66M Perf Week2.11%
Market Cap2.24B Forward P/E- EPS next Y-3.12 Insider Trans-16.37% Shs Float59.36M Perf Month-4.23%
Income-124.90M PEG- EPS next Q-0.68 Inst Own95.30% Short Float / Ratio6.17% / 8.95 Perf Quarter-8.63%
Sales9.40M P/S238.80 EPS this Y-16.80% Inst Trans1.31% Short Interest3.66M Perf Half Y-0.28%
Book/sh10.99 P/B3.26 EPS next Y-10.20% ROA-17.30% Target Price50.85 Perf Year18.82%
Cash/sh9.44 P/C3.79 EPS next 5Y- ROE-17.80% 52W Range24.94 - 41.39 Perf YTD-9.23%
Dividend- P/FCF- EPS past 5Y-3.90% ROI-17.90% 52W High-13.53% Beta1.42
Dividend %- Quick Ratio26.40 Sales past 5Y97.90% Gross Margin- 52W Low43.50% ATR1.49
Employees203 Current Ratio26.40 Sales Q/Q-100.00% Oper. Margin- RSI (14)51.01 Volatility3.97% 4.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.50% Profit Margin- Rel Volume0.71 Prev Close35.61
ShortableYes LT Debt/Eq0.00 EarningsMar 01 AMC Payout- Avg Volume408.76K Price35.79
Recom1.60 SMA202.56% SMA50-3.16% SMA200-0.85% Volume290,055 Change0.51%
Dec-14-22Initiated Goldman Buy $60
Dec-12-22Initiated Cowen Outperform
Nov-28-22Initiated Wells Fargo Overweight $50
Oct-19-22Initiated Raymond James Outperform $52
Aug-29-22Initiated BofA Securities Buy $45
Jul-21-22Initiated JP Morgan Overweight $55
Oct-28-21Initiated RBC Capital Mkts Outperform $43
Oct-02-20Initiated SVB Leerink Outperform $22
Jul-21-20Initiated Needham Buy $22
Jun-01-20Resumed Jefferies Buy $23
Show Previous Ratings
Mar-22-23 04:01PM
Mar-06-23 01:07AM
Mar-04-23 07:48AM
Mar-02-23 05:31AM
Mar-01-23 05:25PM
04:01PM Loading…
Feb-22-23 04:01PM
Feb-08-23 04:01PM
Jan-20-23 05:25AM
Jan-09-23 08:00AM
Jan-04-23 04:01PM
Dec-02-22 08:30AM
Nov-30-22 04:01PM
Nov-29-22 03:17PM
Nov-12-22 07:29AM
04:30PM Loading…
Nov-09-22 04:30PM
Nov-08-22 05:35PM
Nov-07-22 08:30AM
Nov-03-22 08:30AM
Nov-01-22 08:25PM
Oct-19-22 01:36PM
Oct-06-22 03:14PM
Sep-01-22 04:01PM
Aug-29-22 07:14PM
Aug-15-22 07:24PM
Aug-12-22 07:40AM
Aug-09-22 05:15PM
04:01PM Loading…
Aug-08-22 08:30AM
Aug-02-22 04:01PM
Jul-22-22 06:20AM
Jul-11-22 04:01PM
Jun-27-22 02:11PM
Jun-23-22 04:10PM
Jun-22-22 10:27PM
Jun-21-22 07:00AM
Jun-01-22 04:01PM
May-30-22 10:53AM
May-10-22 05:45PM
May-09-22 06:25PM
May-05-22 06:05PM
May-04-22 07:45AM
May-03-22 04:01PM
Apr-29-22 02:25PM
Apr-25-22 04:01PM
Apr-04-22 04:01PM
Mar-22-22 04:01PM
Mar-01-22 05:25PM
Feb-24-22 08:10PM
Feb-22-22 04:01PM
Feb-16-22 08:15AM
Feb-14-22 04:01PM
Feb-06-22 04:40PM
Jan-18-22 05:38PM
Jan-12-22 08:00AM
Jan-10-22 08:30AM
Dec-21-21 11:28AM
Dec-08-21 04:40PM
Dec-03-21 04:16PM
Nov-17-21 11:57AM
Nov-12-21 08:30AM
Nov-10-21 05:15PM
Nov-03-21 04:01PM
Oct-29-21 04:15PM
Oct-28-21 03:06PM
Oct-26-21 12:03PM
Oct-22-21 03:06PM
Oct-18-21 04:12AM
Oct-14-21 12:13PM
Oct-08-21 02:15PM
Oct-06-21 07:18AM
Oct-05-21 09:54PM
Oct-04-21 04:08PM
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KENNEY CHRISTOPHER JOHNChief Medical OfficerMar 24Sale35.0170024,5070Mar 24 07:18 PM
PIMSTONE SIMON N.DirectorMar 07Option Exercise2.6472,016190,22564,866Mar 09 06:21 PM
PIMSTONE SIMON N.DirectorMar 07Sale36.9819,232711,19934,002Mar 09 06:21 PM
AZAB MOHAMMADDirectorDec 12Option Exercise2.683,0868,27069,905Dec 13 04:29 PM
PATOU GARYDirectorNov 25Option Exercise2.682,0575,51325,630Nov 28 08:41 PM
PATOU GARYDirectorNov 25Sale34.791,93767,39023,573Nov 28 08:41 PM
PATOU GARYDirectorNov 23Sale34.332,05770,61023,573Nov 28 08:41 PM
AULIN SHERRYChief Financial OfficerSep 02Option Exercise6.9718,648130,06118,648Sep 07 04:26 PM
AULIN SHERRYChief Financial OfficerSep 02Sale39.5715,355607,5970Sep 07 04:26 PM
ROBIN SHERRINGTONEVP, Strategy & InnovationSep 01Option Exercise4.7550,000237,50066,796Sep 02 04:27 PM
ROBIN SHERRINGTONEVP, Strategy & InnovationSep 01Sale38.1843,8791,675,47616,796Sep 02 04:27 PM
ROBIN SHERRINGTONEVP, Strategy & InnovationAug 31Option Exercise3.1322,48870,44339,720Sep 02 04:27 PM
ROBIN SHERRINGTONEVP, Strategy & InnovationAug 31Sale38.5721,352823,54716,796Sep 02 04:27 PM
PIMSTONE SIMON N.DirectorAug 16Sale38.5152,0582,004,9016,000Aug 16 05:31 PM
PIMSTONE SIMON N.DirectorAug 15Sale37.7633,9421,281,65058,058Aug 16 05:31 PM
EMPFIELD JAMES R.EVP, Drug DiscoveryAug 12Option Exercise4.2465,000275,75075,000Aug 16 05:36 PM
PIMSTONE SIMON N.DirectorAug 12Sale38.2891,1353,488,59892,000Aug 16 05:31 PM
EMPFIELD JAMES R.EVP, Drug DiscoveryAug 12Sale38.3157,7432,211,97810,000Aug 16 05:36 PM